treatment response, then to establish the first step towards optimizing the doses of future trials.
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BACKGROUND
Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) is an effective and curative treatment for many hematological malignancies [1] related to the existence of a graft-versusmalignancy effect. However, it is frequently associated with graft-versus-host disease (GvHD) which is still responsible for a high rate of treatment-related mortality. [2] Acute GvHD usually involves skin, liver and the intestinal tract, but lymphoid and haematopoietic tissues can also be affected. It is induced by alloreactive T-cells from the donor, which react against the recipient's tissues and organs. Standard GvHD prophylaxis consists in administering a combination of immunosuppressive drugs with the classical association of cyclosporine A (CsA) and methotrexate. [3] Other therapeutic approaches have been tested including T-cell depletion, that can be performed in vivo or ex vivo. The incidence of GvHD decreases, but this is at the cost of a high risk of rejection and relapse associated to a delayed immune reconstitution. [4] The first line treatment of aGvHD is based on steroids with usually methylprednisolone (MP) at the dose of 2 to 2.5 mg/kg/day. [5] However, steroid resistance is observed in approximately 40 % of the patients and therefore requires alternative treatment. [6, 7] No standard therapy really exists in steroid-refractory aGvHD. Therapy could be based on high dose of steroids (10 to 15 mg/kg/day) either alone or in combination with antithymocyte globulins or monoclonal anti-T-cell preparations. [8] [9] [10] In some cases, although it cures aGvHD, this treatment is responsible for a strong immunosuppression leading to an increased incidence of severe bacterial, viral infections, and an increased risk of Epstein-Barr Virus (EBV)-related lymphoproliferative disorders. [11, 12] Inolimomab (Leukotac®, OPi, Limonest, France) because of its inhibitory effects on activated Tcells, could be useful for the treatment of aGvHD. This murin monoclonal antibody (mAb) specifically targets the α chain (CD25) of the interleukine-2 (IL2) receptor. Activated T-cells express the inducible IL-2Rα chain whereas resting cells and their precursors do not.
Consequently, fewer adverse experiences are expected, due to a lower and more targeted immunosuppression activity. Some clinical trials have already been performed in steroid-resistant aGvHD and have shown some promising results in terms of response and survival. [13] [14] [15] [16] [17] A clinical trial of inolimomab given in association with steroids, was conducted as initial therapy of aGvHD. As the compound was well tolerated [15] , this clinical trial expected to show a better, longer and less heterogeneous overall response than in steroid-resistant patients. This study presents an original population PK-PD modelling of these clinical data, showing for the first time and in this indication, an exposure-effect relationship of a mAb. The specific aims were: (i) to model the PK of inolimomab given as a repeated dose; (ii) to identify inolimomab exposure-effect relationships on different efficacy markers in aGvHD and (iii) to propose a model in order to help future dose optimization of this treatment. Inclusion criteria were as follows: grade II to IV aGvHD following HSCT using either allogeneic bone marrow or allogeneic peripheral blood progenitor cells, and patients had to be 18 years old with written informed consent to participate in the study. Patients were not included if steroids were part of prophylaxis of aGvHD or in case of aGvHD occurring after the donor lymphocyte infusions. Diagnosis and classification of aGvHD was done according to the Seattle criteria (Glucksberg classification) [18, 19] and the IBMTR [20] classification.
After eligibility was confirmed, 21 patients were registered and assigned to 1 of 4 cohorts to receive 30-minute intravenous (IV) inolimomab infusion (0.10, 0.20, 0.30, and 0.40 mg/kg), with 5 patients in each dose group except 0.30 mg/kg group which had 6 patients. The treatment was divided into the induction and maintenance regimen phases. The induction regimen was given from day 1 to day 8 and consisted in a once daily IV infusion of inolimomab at the patient's assigned dose level. The clinical response assessed at day 9 determined subsequent treatment. Patients with complete response were assigned to receive the maintenance regimen. A total of 21 patients (12 men and 9 women; age range, 29-61 years; weight range, 49-93 kg) were enrolled in the trial (Table I ). According to their initial disease, they could be classified in 3 groups: 6 patients with good prognosis transplantation of success (for CML in chronic phase, AML, or ALL in first complete remission), 9 with intermediate prognosis (for AML, ALL in second complete remission or above, NHL, myeloma, or hodgkin disease in partial response), and 6 with a poor prognosis (disease refractory or in relapse).
PK sampling
The median number of PK samples per patient was 12 (range 7-23) and the total number was 318. Blood samples for PK (including peak and trough levels of inolimomab) were collected on day 1 prior to the infusion then 30 minutes, 2, 8 and 16 after completion of the infusion; prior to the infusion and 30 minutes after completion of the administration of study medication on days 2, 3 and 8; and prior to the infusion and 30 minutes after completion of the administration of study medication from day 9 to day 28 for the first three infusions. After collection, they were centrifuged and serums were stored at -20 °C until analysis.
Bioanalysis
Quantification was then carried out in the OPi Research department by a validated inolimomab Enzyme-Linked ImmunoSorbent Assay (ELISA) according to GLP. To trap inolimomab, serum samples were put on a coated plate with goat polyclonal anti-mouse Ig antibodies (GAM). Next, sheep polyclonal anti-mouse IgG1 antibodies used as tracer antibodies were added to the mixture. After incubation with TMB-substrate, the reaction was stopped by the addition of sulfuric acid and absorption was read photometrically to quantify the samples. The range of the immunoassay was from 0.15 to 10 µg/ml, with a sensitivity > 100 ng/ml, a sample intra-assay variation at 8 % and a sample inter-assay variation at 11%. 
PD assessments
Acute GvHD grades and performance status were evaluated daily until day 9 then at each administration, from day 10 to day 28, as well as at follow-up (day 60 and day 100) using the Glucksberg-Seattle, IBMTR and Karnofsky classifications [21] (defined in the study as composite scores). Glucksberg criteria determines aGvHD severity (from grades 0, corresponding to no GvHD, to 4, maximum severity) by a combination of different organ scores (skin, intestinal tract and liver) and a decrease in clinical performance. These organs are graded independently from 0 to 4 corresponding respectively to extend of a skin rash, a diarrhea volume, and total bilirubin concentrations. The detailed definition of IBMTR score is given in annex 1. Briefly, it involves the same organs but assigns the score based on maximum involvement in an individual organ system. Therefore, it tends to assign a higher overall grade for aGvHD severity than the Glucksberg.
[20] The Karnofsky scale defines overall performance status of a patient from 100% for a normal person with no complaint and no sign of disease to 0 % for a moribund. Independent organs as well as composite scores were considered for pharmacodynamics analysis.
PK analysis
PK and PD analysis were carried out with mixed-effect modeling using NONMEM software version V. [22] Different PK models were tested, including one, two and three compartment models, coupled with linear or nonlinear processes, such as saturable elimination. Inter-individual PK parameter variability was assumed to follow log-normal distribution with non-zero correlations. Residual unexplained variability was modeled as multiplicative. FOCE INTERACTION method was used to fit all PK models. Models were evaluated through goodness of fit plots [23] [24] [25] and the parameter precision estimated by asymptotic covariance matrix.
Nested models were compared according to likelihood ratio tests (decrease of NONMEM objective function between reduced and full model by ∆=3.84, corresponding to nominal p-value 0.05, for one additional parameter).
PK-PD analysis
For each pharmacodynamic time point assessment, inolimomab exposures were estimated from individual PK profiles predicted from the previously described model. They were defined either as maximal serum concentration (C max ), Area Under the serum concentration-time Curve (AUC) over last dosing interval , cumulated AUC, or AUC intensity (cumulated AUC/duration) from the first to the last dosing before PD assessment. Cumulated AUC corresponded to the cumulated sum of all AUCs computed for each dosing interval before PD assessment; duration used in AUC intensity calculation corresponded to the treatment duration before PD assessment.
The graphical exploration of the exposure-effect relationships was performed with all PD assessments by plotting estimated cumulative probabilities of ordered scores (composite and organ scores) vs. distribution quartiles (25, 50, 75 and 100%) of the above defined drug exposures. Apparent relationships were then quantified by proportional odds models. [26] Cumulative probabilities of the observed score were linked to PK exposure through logit transformation. The nature of this link was tested with different PD models, like E max , log-linear or linear models. Inter-patient variability of some key parameters was assumed to follow either a normal or a log normal distribution. Parameter estimation was performed using the Laplacian estimation method in NONMEM. The adequacy of the different developed models and selection of the basic model was evaluated by comparing predicted and observed probabilities.
Model Qualification
The model qualification for PK and PK-PD model was conducted in two steps. In regards to the PK model, after inspection of the basic graphics (predictions of a typical patient versus concentrations with the observed ones. The qualification of the PK-PD model was also based on a visual predictive check. Here, the purpose was to test the model performance in order to predict probabilities to observe the different grades. Therefore, we compared graphically simulated grades function of exposure, with the observed ones. Then, in order to qualify the PK-PD model for its clinical purpose, a predictive check was more specifically conducted. [28, 29] It consisted in simulating (using NONMEM) 1000 new datasets with identical patients, score record time, and then comparing a test statistic deduced from these simulations with observed ones. This test statistic, which is a test quantity that depends only on data was chosen in order to highlight treatment effect.
RESULTS

PK analysis
Amongst all PK models tested, the best results were obtained with a two-compartment model. The goodness of fit plot for this model showed that the mean population and individual predicted concentrations were in good agreement with the observed ones (close to identity) except for a few concentrations over 20µg/ml which were under-predicted. Other tested models included a third compartment or a Michaelis-Menten elimination. The three-compartment model was not identifiable and a non-linear elimination did not show a significant improvement fit, therefore the two-compartment model was eventually retained. The correlation between all PK parameters was then introduced. Parameter estimates are presented on Table II . The half-life of the compound for a typical patient was equal to 44.5h.
The most important goodness-of-fit plots of the final PK model are presented in Figure 1 .
Although it shows a slight under prediction for high concentrations, a visual predictive check ( Figure 2 ) revealed that this has no impact on predicted concentrations: the proportion of concentration points outside the 80 % confidence interval band was in agreement with the expected one. The PK model was consequently considered to be qualified.
PK-PD analysis
PD assessments included composite scores, with a median number per subject of IBMTR scores at 13, ranging (3-23), a median number per subject of Glucksberg scores at 12, ranging , and a median number per subject of Karnofsky scores at 18, ranging (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . Organ scores (skin, intestinal tract or liver) were recorded with a median number per subject at 18, ranging (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . The PK-PD exploratory graphical analysis revealed that composite scores (IBMTR, Glucksberg and Karnofsky) were apparently not related to drug exposure (see Figure 3 with cumulated AUC, other graphics concerning C max , AUC and AUC intensity are not shown). On the contrary, organ scores (skin, intestinal tract and liver) revealed patient improvements (i.e.
HAL author manuscript inserm-00172432, version 1 lowest grade probability increase) when plotted versus drug exposure expressed as cumulated AUC or AUC intensity (see cumulated AUC in Figure 4) . When AUC or C max measured over last dosing interval were used, this relationship was less clear. Consequently, it was chosen to develop the PK-PD model for the 3-organ score cumulated probabilities, conditional on cumulated AUC, and AUC intensity. Based on goodness of fit and parameter uncertainty, only the relationship between cumulated AUC and observed scores was finally considered. In regards to skin, after merging grade 3 and 4 (since only four grades 4 were observed), an E max model with inter-individual variability on logit and EA 50 (cumulated AUC producing 50 % of maximum effect) gave the best results according to equation:
where P(Y≤j) represents the probability to obtain a score Y for skin inferior or equal to the grade j, alpha j represents intercept of the logit for the grade j and γ the coefficient of sigmoïdicity.
Individual EA 50i distribution across the population revealed two groups of patients (i=1 or 2), one with high EA 50 , another with low EA 50 . A mixture probability was then added to EA 50i random effect in order to estimate the proportion of those two sub-populations and their respective Table III .
where Emax model of Equation 1 is replaced by a linear model defined by a slope.
A visual predictive check of the PK-PD models for the three organs ( Figure 5 ) revealed an overall good agreement -between 80 % confidence interval band and observed grade probabilities. The next step consisted in global qualification of the PK-PD analysis. For this purpose we evaluated the model by predictive check. We evaluated whether the combination of the PK model and the 3-organ score models (for skin, intestinal tract and liver), correctly predicted global effect therapy expressed by the IBMTR score. In this way, our model could be used to verify a treatment effect. The chosen test statistics was the number of the observed grade at a given time, either calculated from the observed data or predicted conditional on the model.
Simulation was performed for the overall treatment duration, but test statistic is only presented at treatment start (top of the Figure 6 ) and day 28 (bottom of the Figure 6 ), for which 11 patients remained at treatment end. This graph revealed a good agreement of the 90 % confidence interval band with the observed IBMTR score. The combination of the three models to obtain the IBMTR score is qualified and can be used to define the effect of treatment without modelling the IBMTR score itself. The comparison of the two rows revealed that IBMTR scores decreased with treatment time: IBMTR at day 1 had more probability to be observed at a grade 2 or 3 and eventually 4, whereas at day 28 the highest probability observed and predicted is at grade 0 and then 1 or 2. This observation confirmed the global therapy effect as it was already shown in PKPD profiles of each organ. Our study modeled the PK of inolimomab and succeeded to model its exposure-effect relationship. For PK modeling, the population approach taking into account design heterogeneity and individual treatment history, allowed to identify a two-compartment model. Despite some under predictions in the higher concentrations, observations were on the whole well predicted and the model was qualified for calculating individual treatment exposure, which could not be directly computed from the observed data.
To highlight PK-PD relationships, we initially considered aGvHD according to It is illustrated by a large decrease of patients with severe symptoms (grade 4) and an important increase of patients without symptoms (grade 0). This means that a larger exposure than for skin is required to reach same efficacy for those organs. It also explains why clinically, skin is the first organ to be cured whereas it seems to be more difficult to treat the liver and the intestinal tract. It is illustrated by PK-PD graphs at day 8: from 15 to 20 % of patients still present highest grade for these two organs. Some authors have explained this phenomenon by the difference of bioavailability or pathophysiology of aGvHD depending on organ involvement.
[32]
Although the modelling of the IBMTR score could not be performed, this approach allowed us to easily simulate this score by the combination of the three organs on which it is based. It was also possible to use it to define the overall response at the end of treatment and therefore to verify a treatment effect. However, the benefit of this type of approach is that it takes into account the time dependency of the data. In this way, our models can predict the effect for a given patient and a treatment schedule, in function of time throughout the study (see Figure 7) and also give a more precise idea of the disease evolution under treatment. It is also possible to know if one organ presents a rapid or a slow remission. However, these predictions for the time being must be used with caution. As in our models, the effect is related to cumulated AUC and we modelled the PK-PD relationship by positive monotonous functions, predicted effects automatically increase with time. Therefore, no aGvHD relapse could be predicted by the model.
Moreover, based on cumulated AUC, we will obtain the same response for a concentration y during x hours or a concentration x during y hours, regardless of the values of x and y.
[39] In these conditions, the dosage or regimen optimization based on modelling is not possible. In fact,
we used cumulated AUC because we assumed there would be a delay between concentrations and effect. In our case, the nature of the PD data did not allow us to model this delay in another way. However, perspectives of this work, with future data, will be to link scores to serum concentrations using a more physiologic model taking into account drug and effect accumulation.
In this case, dosage and regimen optimization of future trial as well as individual therapeutic monitoring of patients could be performed.
CONCLUSION
Finally, with this analysis, we highlighted and modelled a PK-PD relationship between cumulated AUC of inolimomab and skin, liver and intestinal tract scores. The modelling of the data allowed us to describe observations as well as to predict an overall response at the end of treatment for this population through scores of IBMTR. This approach, validated for its objective, allowed us to understand better the treatment effect over time and represents the first step towards optimizing the doses of future patients. However, it does still present some limitations, due in particular to the limited number of available patients. They were clearly identified, and future trials are needed to improve clinical use of these models. Severe pain and ileus a assign index based on maximum involvement in an individual organ system. observed IBMTR in 21 patients at treatment start (top row) and in 11 patients still in the study at day 28 (bottom row). 
